Mosaiques Diagnostics
Hannoversch M├╝nden
About Mosaiques Diagnostics
Mosaiques Diagnostics focuses on the detection of diseases enabling personalized medicine during therapy and drug development. The company utilizes diagnostic polypeptide patterns (DiaPat) derived from the fast and accurate analysis of proteins and polypeptides in body fluids (e.g. urine, bile and cerebrospinal fluid). For this purpose, mosaiques has developed a unique technology on the basis of clinical proteome analysis, enabling the early and differential detection of cardiovascular, renal, biliary and urogenital diseases. Furthermore, diagnostic tests for additional indications, such as Alzheimer's disease, pancreatic cancer and nephrotoxic effects of drugs are in development. Diagnosis is accomplished by highly specific patterns of multiple simultaneously detected biomarkers (proteins/polypeptides) from patient samples obtained in a risk-free and painless procedure. Mosaiques utilizes high resolution capillary electrophoresis coupled mass spectrometry (CE-MS technology), which enables the separation of body fluids in less than one hour. Proprietary software affords the analysis of huge amounts of data within minutes.
Company Facts
- Operating status: Active
- Company type: For Profit
- IPO status: Private
- Employees: 11 – 50
- Total funding: $68.3K
- Funding stage: Seed
- Last round: Seed (Jan 2014)
- Website: mosaiques-diagnostics.de
- Phone: +49 (0)511 55 47 44 0
Industries & Categories
Biotechnology, Health Care, Health Diagnostics, Precision Medicine
Social Profiles
Canonical: https://fsome.com/organization/mosaiques-diagnostics-3081313 · For the full interactive profile (charts, investors, team, acquisitions, press), please enable JavaScript.